Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Conditions
Brief summary
This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Detailed description
PRIMARY OBJECTIVES: I. To determine the objective response rate in patients with advanced or metastatic colorectal cancer treated with SB-715992 once a week for 3 weeks, every 28 days and SB-715992 once every 21 days. SECONDARY OBJECTIVES: I. To determine the time to tumor progression, progression free and overall survival of patients and toxicity in patients with advanced or metastatic colorectal cancer treated with SB-715992 once a week for 3 weeks, every 28 days and SB-715992 once every 21 days. II. To characterize the population pharmacokinetic (PK) parameters of SB-715992 including an assessment of significant covariates on SB-715992 PK and an assessment of the potential relationships between the pharmacokinetics of SB-715992 and relevant safety and efficacy endpoints. IV. To examine cytoskeletal morphology changes in response to SB-715992 in peripheral blood mononuclear cells and tumors by fluorescent immunohistochemistry. V. To evaluate mRNA expression of betaΙΙΙ-tubulin and KSP in archival tumor tissue. VI. To determine the frequency of genomic polymorphisms in genes targeted by SB-715992 (measured in peripheral blood mononuclear cells) and to assess whether germline polymorphisms (DNA) of genes targeted by SB-715992 (KSP inhibitor) are associated with toxicity and clinical outcome in patients with colorectal cancer. Further, whether genes involved with the metabolism (CYP3A4) and resistance (MDR1) affect the outcome in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
Interventions
DRUGispinesib
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed advanced/metastatic colorectal cancer * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral CT scan * Patients must have received prior therapy (in any setting) with 5-FU, CPT-11, and oxaliplatin; patients may have received prior erbitux and bevacizumab, but it is not required * Patients must have received at least one prior chemotherapy regimen for advanced disease * Tumor must be accessible for biopsy or paraffin embedded tissue must be available for review of their biopsy specimen * Life expectancy of \> 12 weeks * ECOG performance status 0-2 (Karnofsky \>= 50%) * Leukocytes \>= 3,000/μL * Absolute neutrophil count \>= 1,500/μL * Platelets \>= 100,000/μL * Hemoglobin \>= 9 mg/dL * Total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) =\< 2.5 X institutional upper limit of normal * Creatinine =\< 1.5 X institutional upper limit of normal OR creatinine clearance \>= 60 mL/min/1.73 m\^2 * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from AEs due to agents administered more than 4 weeks earlier * Patients may not have received any other investigational agents within 28 days of study entry * Patients may not receive other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study * Prohibited medications; SB-715992 is a moderate to significant in vitro inhibitor of CYP3A4; the following lists of medications/substances are moderate to significant inhibitors/inducers of CYP3A4 that, if administered concomitantly with SB-715992, may alter study drug exposure; the use of these medications/substances within 14 days (\> 6 months for amiodarone) prior to the administration of the first dose of SB-715992 through discontinuation from the study is prohibited * Inhibitors of CYP3A4: * Antibiotics: clarithromycin, erythromycin, troleandomycin * Antifungals: itraconazole, ketoconazole, fluconazole (doses \> 200 mg/day), voriconazole * Antidepressants: nefazodone, fluovoxamine * Calcium channel blockers: verapamil, diltiazem * Miscellaneous: amiodarone\*, grapefruit juice, bitter orange * Use of amiodarone within 6 months prior to the administration of the first dose of SB-715992 is prohibited * Inducers of CYP3A4: * Anticonvulsants: phenytoin, carbamazepine, Phenobarbital, oxcarbazepine * Antibiotics: rifampin, rifabutin, rifapentine * Miscellaneous: St. John's wort, modafinil * Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * History of allergic reactions attributed to compounds of similar chemical or biologic composition to SB-715992 * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SB-715992 * HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response (CR or PR) as Determined by the RECIST Criteria | Up to 5 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | From the date of registration to the date of documented PSA progression, assessed up to 6 months | Will be estimated using the product-limit method of Kaplan and Meier by arm. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Overall Survival | From the date of registration to the date of death, assessed up to 12 months | Will be estimated using the product-limit method of Kaplan and Meier by arm. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients receive SB-715992 IV at 7 mg/m2 over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ispinesib: Given IV
laboratory biomarker analysis: Correlative studies | 33 |
| Arm II Patients receive SB-715992 IV at 18 mg/m2 over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ispinesib: Given IV
laboratory biomarker analysis: Correlative studies | 31 |
| Total | 64 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 1 |
Baseline characteristics
| Characteristic | Arm I | Arm II | Total |
|---|---|---|---|
| Age, Continuous | 59 years | 60 years | 59 years |
| Region of Enrollment United States | 33 participants | 31 participants | 64 participants |
| Sex: Female, Male Female | 14 Participants | 13 Participants | 27 Participants |
| Sex: Female, Male Male | 19 Participants | 18 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 33 / 33 | 31 / 31 |
| serious Total, serious adverse events | 14 / 33 | 13 / 31 |
Outcome results
Primary
Objective Response (CR or PR) as Determined by the RECIST Criteria
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Up to 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Objective Response (CR or PR) as Determined by the RECIST Criteria | 0 participants |
| Arm II | Objective Response (CR or PR) as Determined by the RECIST Criteria | 0 participants |
Secondary
Overall Survival
Will be estimated using the product-limit method of Kaplan and Meier by arm.
Time frame: From the date of registration to the date of death, assessed up to 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I | Overall Survival | 3.6 months |
| Arm II | Overall Survival | 4.5 months |
Secondary
Progression-free Survival
Will be estimated using the product-limit method of Kaplan and Meier by arm. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From the date of registration to the date of documented PSA progression, assessed up to 6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I | Progression-free Survival | 7.0 weeks |
| Arm II | Progression-free Survival | 5.3 weeks |